Skip to Main Content

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Conditions

Lung

Phase I

What is the purpose of this trial?

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors.

  • Trial with
    Amgen, Inc.
  • Start Date
    07/30/2020
  • End Date
    12/14/2021

For more information about this study, contact:

Kira Fitzsimons Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/13/2020
  • Study HIC
    #2000026544